EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Lower Dose‐Normalized Tacrolimus Exposure in CYP3A5 *6 vs. *3 Loss‐of‐Function Allele Carriers: A Longitudinal Retrospective Real‐World Study in Kidney Transplant Recipients

Amar D Levens iD, Dirk Jan A R Moes iD, Yanick Boer, Aiko P J de Vries iD, Dorottya K de Vries iD, Danny van der Helm iD, Soufian Meziyerh iD, Dave L Roelen iD, Stefan Böhringer iD, Teun Van Gelder iD, Jesse J Swen iD

Clinical Pharmacology & Therapeutics · 2026-04 · 119 (4) · 942-952

DOI: 10.1002/cpt.70162 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 22.12.2025. Verfasst von Amar D Levens und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Tacrolimus, Kidney Transplantation, Immunosuppressive Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacogenomic research has historically focused on individuals of European ancestry, leading to the underrepresentation of genetic variants common in non‐European populations. This bias is exemplified by CYP3A5 *6, a functionally consequential variant common in individuals of African ancestry (MAF: 11–19%) but virtually absent in Europeans (MAF: 0.15%). We conducted a retrospective, longitudinal cohort study using real‐world data from 1,461 adult kidney transplant recipients across 67 countries, analyzing 4,293 dose‐normalized 24‐hour area‐under‐the‐curve (AUC 0‐24 ) measurements of tacrolimus. Patients with CYP3A5* 1/*1 were excluded. Linear mixed‐effects models (LME) were used to assess the association between CYP3A5* 6 carriage and tacrolimus exposure, adjusting for clinical factors and ancestry using both HLA‐based principal components and country of birth. CYP3A5 *6 carriers had a 17% lower dose‐normalized AUC 0‐24 than CYP3A5 *3 carriers ( P = 0.015). Sensitivity analyses using dose‐normalized trough concentrations (C 0 ) confirmed these findings, with a 20% lower exposure in CYP3A5 *6 carriers ( P = 0.011). An interval‐based analysis demonstrated persistently lower tacrolimus exposure across the first post‐transplant year. All CYP3A5 *6‐containing genotypes showed significantly lower dose‐normalized AUC 0‐24 compared to CYP3A5 *3/*3, the most common genotype in European populations, with the largest reductions observed in CYP3A5 *1/*6 (−39%; P < 0.001) and CYP3A5 *3/*6 (−18%; P = 0.006). African origin, defined by country of birth, was independently associated with a 23% higher AUC 0‐24 ( P < 0.001). This is the first study to demonstrate a differential effect on tacrolimus exposure between the CYP3A5 *6 and CYP3A5 *3 loss‐of‐function alleles. Our results may help bridge the ethnicity gap, advance the applicability of pharmacogenomic findings, and promote health equity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP3ATacrolimusKidney TransplantationImmunosuppressive AgentsHumansMaleRetrospective StudiesFemaleLongitudinal StudiesMiddle AgedAdultAllelesArea Under CurveBlack PeopleWhite PeopleHeterozygoteAged

Substanzen

Cytochrome P-450 CYP3ATacrolimusImmunosuppressive AgentsCYP3A5 protein, human

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
  • Division of Nephrology, Department of Medicine, Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.
  • Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Surgery, Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands.

ORCID-Profile: Amar D Levens, Dirk Jan A R Moes, Aiko P J de Vries, Dorottya K de Vries, Danny van der Helm, Soufian Meziyerh, Dave L Roelen, Stefan Böhringer, Teun Van Gelder, Jesse J Swen

Zitieren

APA

Levens, A. D., Moes, D. J. A. R., Boer, Y., de Vries, A. P. J., de Vries, D. K., van der Helm, D., Meziyerh, S., Roelen, D. L., Böhringer, S., Van Gelder, T., & Swen, J. J. (2026). Lower Dose‐Normalized Tacrolimus Exposure in CYP3A5 *6 vs. *3 Loss‐of‐Function Allele Carriers: A Longitudinal Retrospective Real‐World Study in Kidney Transplant Recipients. Clinical Pharmacology & Therapeutics, 119(4), 942-952. https://doi.org/10.1002/cpt.70162

Vancouver

Levens AD, Moes DJAR, Boer Y, de Vries APJ, de Vries DK, van der Helm D, et al. Lower Dose‐Normalized Tacrolimus Exposure in CYP3A5 *6 vs. *3 Loss‐of‐Function Allele Carriers: A Longitudinal Retrospective Real‐World Study in Kidney Transplant Recipients. Clinical Pharmacology & Therapeutics. 2026;119(4):942-952. doi:10.1002/cpt.70162

BibTeX
@article{Levens2026,
  author = {Levens, Amar D and Moes, Dirk Jan A R and Boer, Yanick and de Vries, Aiko P J and de Vries, Dorottya K and van der Helm, Danny and Meziyerh, Soufian and Roelen, Dave L and Böhringer, Stefan and Van Gelder, Teun and Swen, Jesse J},
  title = {Lower Dose‐Normalized Tacrolimus Exposure in CYP3A5 *6 vs. *3 Loss‐of‐Function Allele Carriers: A Longitudinal Retrospective Real‐World Study in Kidney Transplant Recipients},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  volume = {119},
  number = {4},
  pages = {942--952},
  doi = {10.1002/cpt.70162}
}
Kostenlos starten →